about
2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesHigh-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesSeattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators.Total Artificial Heart as Bridge to Transplantation for Severe Culture-Negative Prosthetic Valve Endocarditis Due to Gemella haemolysansMultiple biomarkers for risk prediction in chronic heart failure.Treatment of functional mitral regurgitation by percutaneous annuloplasty: results of the TITAN TrialTools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failureThe effect of aging on phenylephrine response in normal subjects.Fatigue, inflammation, and projected mortality in heart failure.Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure.Cost-Effectiveness Analysis of Iodine-123 Meta-Iodobenzylguanidine Imaging for Screening Heart Failure Patients Eligible for an Implantable Cardioverter Defibrillator in the USAAssociations between Seattle Heart Failure Model scores and health utilities: findings from HF-ACTIONFrom statistical significance to clinical relevance: A simple algorithm to integrate brain natriuretic peptide and the Seattle Heart Failure Model for risk stratification in heart failureMaximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population.Time-dependent Predictive Values of Prognostic Biomarkers with Failure Time Outcome.Percutaneous mitral annuloplasty for functional mitral regurgitation: results of the CARILLON Mitral Annuloplasty Device European Union Study.Establishing prognosis in heart failure: a multimarker approach.Multivariate risk scores and patient outcomes in advanced heart failure.Safety and efficacy of the MitraClip® system for severe mitral regurgitation: a systematic review.Accuracy of Seattle Heart Failure Model and HeartMate II Risk Score in Non-Inotrope-Dependent Advanced Heart Failure Patients: Insights From the ROADMAP Study (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and MedicOpportunity to increase life span in narrow QRS cardiac resynchronization therapy recipients by deactivating ventricular pacing: evidence from randomized controlled trials.Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models.Systematic donor selection review process improves cardiac transplant volumes and outcomes.Can preeclampsia be considered a renal compartment syndrome? A hypothesis and analysis of the literature.Agreement between risk and priority for heart transplant: Effects of the geographic allocation rule and status assignment.Evaluating the ROC performance of markers for future events.Mortality prediction using a modified Seattle Heart Failure Model may improve patient selection for ventricular tachycardia ablation.Comparison of Multivariate Risk Estimation Models to Predict Prognosis in Patients With Implantable Cardioverter Defibrillators With or Without Cardiac Resynchronization Therapy.The Seattle Heart Failure Model: prediction of survival in heart failure.Application and comparison of the FADES, MADIT, and SHFM-D risk models for risk stratification of prophylactic implantable cardioverter-defibrillator treatment.Improved outcome with repeated intracoronary injection of bone marrow-derived cells within a registry: rationale for the randomized outcome trial REPEAT.A novel method to predict the proportional risk of sudden cardiac death in heart failure: Derivation of the Seattle Proportional Risk Model.Prognostic Impact of Implementation of QRS Characteristics in the Seattle Heart Failure Model in ICD and CRT-D Recipients.The effect of duration of follow-up and presence of competing risk on lifespan-gain from implantable cardioverter defibrillator therapy: who benefits the most?An Intervention to Enhance Goals-of-Care Communication Between Heart Failure Patients and Heart Failure ProvidersAssessment of the Effects of Age, Gender, and Exercise Training on the Cardiac Sympathetic Nervous System Using Positron Emission Tomography Imaging.Exercise training bradycardia is largely explained by reduced intrinsic heart rate.Incidence, predictors, and temporal trends of sudden cardiac death after heart transplantation.
P50
Q22306358-3C224809-F2DC-4002-909D-59039066A0B7Q24610732-39ED5D90-826E-440B-AEEF-B3C53FB79551Q26864648-F8106E93-DC08-474A-91A7-93C75197A355Q29620107-0D01DBF4-7860-4A4E-B966-7BBFB4B4303BQ30252338-7972A298-9B5A-4C04-B342-6EACA6941B6CQ35220492-6114B5AB-6A7B-461A-A0BD-76A47D1402CEQ36070049-190593F6-BCD1-401A-8E32-7F85EBAB30F6Q36111525-28710CDB-8FA1-4B8D-95D1-18155BA147DAQ36263401-48E0B4D5-323A-456C-95A2-16307E239B6CQ36275089-6026029B-A52C-48EC-A49D-D1F78DC2D4A7Q36359822-1A78A305-D23C-4627-9C3D-180FA54424D3Q36758142-BB53B3B0-FC79-4D5C-A688-9FF45710D2A5Q36914073-C377A2F9-44B8-4F92-B60B-72D99567DDF9Q37007658-A2F1DF57-5ECB-4A28-8231-90B0D672F8A5Q37029837-35AFCBD1-B3DD-4E3C-B2A1-3F103D5DAEB9Q37176222-3A36E51A-FFF4-410D-9F16-F8F454BDE400Q37286571-94C29B88-061E-487F-BE49-B9969E8630D2Q37637856-E2CCD33D-FC82-4E71-854D-95D214AE5084Q37923531-72937B13-42F2-4D55-964A-632BE9BC0B88Q37929862-31E93ED0-0B10-4DFD-8ACE-C7F0EFCD1012Q38170055-1BBF282B-B433-46FD-ADB8-B2FBF6A47BE8Q38377279-DF790D8A-A50D-4E93-81CA-87AC74C58145Q38377406-071D9F09-A8CD-446D-AA9C-4E88D9E8C1FAQ38571973-4E511B44-52C3-4D5E-90FF-4A5B4EFA3C3EQ38597280-6128E431-CD78-42EC-8DE3-C98088165E67Q38983375-C79260BD-19A7-454E-B5A1-34E31C895DA6Q38993725-3FA09B6D-EA28-441A-B620-FCD809EC5328Q40146249-8F0477FA-D57E-4A57-AC2A-D2F82BBA5B1CQ40200635-8FAB00B9-B895-4E88-AE33-4FA1A37C1BA0Q40304583-5095F1CB-8523-4BC8-B367-A9D526FCF6DEQ40343385-9696FF20-5D39-4824-8A65-9B8D9A69BA20Q40361284-BA2F79CD-0B4F-443A-8A77-0DD0B5127792Q40376706-CA209D08-9395-4E68-82BD-9E6E01FC735FQ40769291-F6C3CD1F-52B7-48B8-B634-ACAEF4D49548Q40827399-CD57AA95-EE25-4168-924E-B99EDF69704CQ41019593-F25552E5-5552-43CF-A672-692AA39739B3Q41264773-8B75E180-8930-48EC-95CA-4F37349892FBQ41974343-3DF60EB6-4BD3-4F05-883A-821293128155Q42618262-172BF5A3-3C57-407E-9DC1-3E984DB08AC6Q42673232-D390F6D9-9708-4368-A307-DACF9C31E1B2
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Wayne C Levy
@es
Wayne C. Levy
@en
Wayne C. Levy
@nl
Wayne C. Levy
@sl
type
label
Wayne C Levy
@es
Wayne C. Levy
@en
Wayne C. Levy
@nl
Wayne C. Levy
@sl
prefLabel
Wayne C Levy
@es
Wayne C. Levy
@en
Wayne C. Levy
@nl
Wayne C. Levy
@sl
P106
P1153
7102141797
P21
P31
P496
0000-0003-1530-2194
P569
2000-01-01T00:00:00Z